Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.37 |
| ▸ | MMP9 | P14780 | 3/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495675 | 0.83 | HDAC6 (0.44) | KCNT1GAAMAPTHTTMMP1 | |
| SCHEMBL6484182 | 0.82 | MMP1 (0.50) | KCNT1GAAMAPTHTTMMP1 | |
| SCHEMBL6493363 | 0.81 | BACE1 (0.36) | — | |
| SCHEMBL6481968 | 0.80 | HDAC8 (0.44) | KCNT1GAAMAPTHTTKMT2A | |
| SCHEMBL6482403 | 0.79 | HDAC6 (0.43) | KCNT1GAAMAPTHTTMMP1 | |
| SCHEMBL8792189 | 0.79 | GHSR (0.53) | KCNT1GAAMAPTHTTMMP2 | |
| SCHEMBL6491342 | 0.79 | GHSR (0.53) | KCNT1GAAMAPTHTTMMP2 | |
| SCHEMBL6495989 | 0.77 | MAPT (0.45) | KCNT1GAAMAPTHTTMMP1 | |
| SCHEMBL8790279 | 0.77 | MAPT (0.46) | KCNT1GAAMAPTHTTMMP1 | |
| SCHEMBL6492948 | 0.76 | BCHE (0.42) | KCNT1GAAMAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | KCNT1 3667/4885GAA 54/4885MAPT 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.